Biomarin Pharmaceutical Inc (BMRN.OQ)
BMRN.OQ on NASDAQ Stock Exchange Global Select Market
81.60USD
22 Jul 2019
81.60USD
22 Jul 2019
Change (% chg)
-- (--)
-- (--)
Prev Close
$81.60
$81.60
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
429,668
429,668
52-wk High
$106.69
$106.69
52-wk Low
$79.15
$79.15
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2019 | Mar '19 | 400.74 | -0.317 |
| FY 2018 | Dec '18 | 353.21 | -0.021 |
| Sep '18 | 391.71 | -0.071 | |
| Jun '18 | 372.85 | -0.095 | |
| Mar '18 | 373.45 | -0.277 | |
| FY 2017 | Dec '17 | 358.30 | -0.052 |
| Sep '17 | 334.15 | -0.072 | |
| Jun '17 | 317.45 | -0.211 | |
| Mar '17 | 303.74 | -0.094 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-19 | 17 | 434.19 | 454.10 | 422.70 | 441.58 |
| Quarter Ending Dec-19 | 17 | 446.29 | 464.90 | 411.70 | 443.62 |
| Year Ending Dec-19 | 23 | 1,697.82 | 1,729.00 | 1,662.00 | 1,731.10 |
| Year Ending Dec-20 | 22 | 1,959.48 | 2,122.00 | 1,775.00 | 1,999.66 |
| Earnings (per share) | |||||
| Quarter Ending Sep-19 | 15 | -0.02 | 0.16 | -0.09 | 0.11 |
| Quarter Ending Dec-19 | 15 | -0.05 | 0.08 | -0.18 | 0.04 |
| Year Ending Dec-19 | 18 | -0.48 | -0.34 | -0.71 | 0.19 |
| Year Ending Dec-20 | 19 | 0.30 | 1.31 | -0.59 | 1.13 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 30.63 | 34.52 | |
| P/E High - Last 5 Yrs. | -- | 47.56 | 54.21 | |
| P/E Low - Last 5 Yrs. | -- | 27.40 | 28.29 | |
| Beta | 1.35 | 1.00 | 0.99 | |
| Price to Sales (TTM) | 9.62 | 6.17 | 7.97 | |
| Price to Book (MRQ) | 4.97 | 3.94 | 4.45 | |
| Price to Tangible Book (MRQ) | 6.48 | 4.25 | 5.18 | |
| Price to Cash Flow (TTM) | 2,640.92 | 22.45 | 24.33 | |
| % Owned Institutions | -- | 0.77 | 1.75 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.78 | 1.63 | |
| Dividend Yield - 5 Year Avg | -- | 1.48 | 1.37 | |
| Dividend 5 Year Growth Rate | -- | 6.75 | 6.83 | |
| Payout Ratio(TTM) | -- | 51.44 | 47.44 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 7.31 | 12.77 | 14.69 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 9.77 | 6.32 | 8.20 | |
| Sales - 5 Yr. Growth Rate | 22.14 | 8.37 | 9.46 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -14.32 | 16.93 | 18.14 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 17.71 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 5.65 | 7.10 | |
| Capital Spending - 5 Yr. Growth Rate | 17.28 | 6.92 | 7.89 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 2.76 | 2.54 | 2.54 |
| Current Ratio (MRQ) | 3.83 | 3.58 | 3.54 |
| LT Debt to Equity (MRQ) | 28.72 | 11.58 | 12.58 |
| Total Debt to Equity (MRQ) | 28.82 | 16.07 | 17.60 |
| Interest Coverage (TTM) | -10.10 | 7.58 | 14.89 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 78.79 | 51.26 | 50.19 | |
| Gross Margin - 5 Yr. Avg. | 81.28 | 50.50 | 51.31 | |
| EBITD Margin (TTM) | -6.87 | -- | -- | |
| EBITD - 5 Yr. Avg | -10.83 | 17.60 | 16.45 | |
| Operating Margin (TTM) | -8.77 | -2.00 | -6.60 | |
| Operating Margin - 5 Yr. Avg. | -20.61 | 13.93 | 11.94 | |
| Pre-Tax Margin (TTM) | -9.54 | -2.33 | -6.95 | |
| Pre-Tax Margin - 5 Yr. Avg. | -23.18 | 18.81 | 15.91 | |
| Net Profit Margin (TTM) | -5.90 | -6.01 | -10.73 | |
| Net Profit Margin - 5 Yr. Avg. | -19.56 | 14.13 | 11.28 | |
| Effective Tax Rate (TTM) | -- | 20.21 | 20.55 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 22.94 | 24.50 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 532,998 | 1,019,456,199 | 879,617,670 | |
| Net Income/Employee (TTM) | -31,427 | 119,302,590 | 102,957,990 | |
| Receivable Turnover (TTM) | 4.27 | 5.64 | 5.90 | |
| Inventory Turnover (TTM) | 0.64 | 2.60 | 3.64 | |
| Asset Turnover (TTM) | 0.34 | 0.89 | 0.85 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -1.98 | 10.55 | 10.25 | |
| Return on Assets - 5 Yr. Avg. | -5.98 | 11.72 | 11.20 | |
| Return on Investment (TTM) | -2.31 | 13.02 | 12.69 | |
| Return on Investment - 5 Yr. Avg. | -6.84 | 14.83 | 14.18 | |
| Return on Equity (TTM) | -3.12 | 14.18 | 17.17 | |
| Return on Equity - 5 Yr. Avg. | -9.33 | 15.93 | 15.55 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 13.52 | 18.78 | 22.14 |
| EPS (TTM) % | -1.77 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Biomarin Pharmaceutical Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -7.21 | -8.03 | 93 | 68 |
| 13 Week | -1.91 | -4.27 | 99 | 55 |
| 26 Week | -16.50 | -25.08 | 99 | 20 |
| 52 Week | -20.71 | -25.29 | 99 | 69 |
| YTD | -4.20 | -19.32 | 99 | 25 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 0.00% |
| # of Holders: | 707 |
| Total Shares Held: | 182,488,015 |
| 3 Mo. Net Change: | 211,990 |
| # New Positions: | 9 |
| # Closed Positions: | 5 |
| # Increased Positions: | 52 |
| # Reduced Positions: | 41 |
| # Net Buyers: | 11 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.